These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. In type 2 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA Lockhart MJ; Dinneen SF Ann Intern Med; 2023 Jul; 176(7):JC81. PubMed ID: 37399561 [TBL] [Abstract][Full Text] [Related]
10. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial. Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751 [TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Philis-Tsimikas A; Bajaj HS; Begtrup K; Cailleteau R; Gowda A; Lingvay I; Mathieu C; Russell-Jones D; Rosenstock J Diabetes Obes Metab; 2023 Feb; 25(2):331-341. PubMed ID: 36106652 [TBL] [Abstract][Full Text] [Related]
12. In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA Griffin TP; Dinneen SF Ann Intern Med; 2021 Mar; 174(3):JC34. PubMed ID: 33646841 [TBL] [Abstract][Full Text] [Related]
13. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O; N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066 [TBL] [Abstract][Full Text] [Related]
15. In type 1 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA Lockhart MJ; Dinneen SF Ann Intern Med; 2023 Jul; 176(7):JC80. PubMed ID: 37399552 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572 [TBL] [Abstract][Full Text] [Related]
18. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB; JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Battelino T; Bergenstal RM; Rodríguez A; Fernández Landó L; Bray R; Tong Z; Brown K Lancet Diabetes Endocrinol; 2022 Jun; 10(6):407-417. PubMed ID: 35468321 [TBL] [Abstract][Full Text] [Related]
20. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes. Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]